TGTX — TG Therapeutics Inc. stock price and chart

Share this page

TGTX

$53.97-3.62%

as of close, Oct 16, 2026

☾ AH $53.97 -3.62%

TG Therapeutics Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%Russell 3000 0.01%US Stock Market 0.01%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

5.010.015.020.025.030.035.040.045.050.055.0050.0M100.0M$53.97

2026-10-16

Price$53.97

MA20$50.72

MA50$39.28

Vol8.2M

What would $1,000 invested in TGTX be worth today? →

TGTX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $53.97
YTD price return: +81.05%
YTD total return: +81.05%
Next earnings: Nov 2, 2026
Market cap: 8.3B2016-12 254.5M2026-10 8.3B+3147.8% over the window
Enterprise value: 8.4B
Shares outstanding: 153.1M2016-06 54.5M2026-06 153.1M+181.1% over the window
52W low: $26.76
52W high: $59.30
From 52W high: -8.99%
From 52W low: +101.68%
52W range: 84%

Volume

Rel volume: 1.04×
30D volume: 1.7M
30D $ vol: 94.5M

Fundamentals

Sales (ttm): 799.5M2016-12 152K2026-06 799.5M+525910.5% over the window
Sales/share: $5.222016-12 $0.002026-06 $5.22+195462.0% over the window
EPS (ttm): $2.772020-12 -$2.422026-06 $2.77-214.4% over the window
FCF (ttm): 17.4M2016-06 -53.4M2026-06 17.4M-132.5% over the window
FCF/share: $0.112016-06 -$0.982026-06 $0.11-111.6% over the window
Book value/share: $3.952016-06 $1.452026-06 $3.95+173.1% over the window
Net margin: 55.22%2016-12 -51482.2%2026-06 55.2%-100.1% over the window
ROE: 73.08%2016-06 -77.5%2026-06 73.1%-194.3% over the window
ROA: 26.93%2016-06 -64.4%2026-06 26.9%-141.8% over the window
Debt / equity: 1.23×2016-06 0.002026-06 1.23+107128.5% over the window
Current ratio: 4.272016-06 4.932026-06 4.27-13.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +76.15%2025-06-30 → 2026-06-30454.1M → 799.5M (+76.1% total)+221.45%2023-06-30 → 2026-06-3024.1M → 799.5M (+3224.3% total)+219.22%2021-06-30 → 2026-06-302.4M → 799.5M (+33020.8% total)+146.54%2016-12-31 → 2026-06-30152K → 799.5M (+525910.5% total)
Net income: +631.24%2025-06-30 → 2026-06-3060.5M → 441.5M (+630.2% total)n/an/an/a
Shares: -3.53%2025-06-30 → 2026-06-30158.7M → 153.1M (-3.5% total)+0.46%2023-06-30 → 2026-06-30151M → 153.1M (+1.4% total)+1.39%2021-06-30 → 2026-06-30142.8M → 153.1M (+7.2% total)+10.89%2016-06-30 → 2026-06-3054.5M → 153.1M (+181.1% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +641.11%2025-06-30 → 2026-06-30$0.37 → $2.77 (+640.1% total)n/an/an/a
Sales/share: +82.60%2025-06-30 → 2026-06-30$2.86 → $5.22 (+82.5% total)+219.98%2023-06-30 → 2026-06-30$0.16 → $5.22 (+3178.9% total)+214.83%2021-06-30 → 2026-06-30$0.02 → $5.22 (+30805.7% total)+122.15%2016-12-31 → 2026-06-30$0.00 → $5.22 (+195462.0% total)
Book value/share: +126.65%2025-06-30 → 2026-06-30$1.74 → $3.95 (+126.5% total)+145.08%2023-06-30 → 2026-06-30$0.27 → $3.95 (+1372.9% total)+8.03%2021-06-30 → 2026-06-30$2.68 → $3.95 (+47.1% total)+10.57%2016-06-30 → 2026-06-30$1.45 → $3.95 (+173.1% total)
Price: +54.82%2025-10-16 → 2026-10-16$34.87 → $53.97 (+54.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+99.44%2023-10-16 → 2026-10-16$6.80 → $53.97 (+693.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.13%2021-10-15 → 2026-10-16$33.31 → $53.97 (+62.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+23.39%2016-10-14 → 2026-10-16$6.59 → $53.97 (+719.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +54.82%2025-10-16 → 2026-10-16$34.87 → $53.97 (+54.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+99.44%2023-10-16 → 2026-10-16$6.80 → $53.97 (+693.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.13%2021-10-15 → 2026-10-16$33.31 → $53.97 (+62.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+23.39%2016-10-14 → 2026-10-16$6.59 → $53.97 (+719.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 19.5×2016-12 -3.532026-10 18.72-631.1% over the window
Fwd P/E: 20.2×
P/S (ttm)Market cap ÷ TTM revenue.: 10.3×2017-03 5117.962026-10 10.34-99.8% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 13.7×2016-12 4.482026-10 13.68+205.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 475.2×2016-12 -4.412026-10 475.45-10893.0% over the window
EV/EBITDA (fy): 61.6×
EV/Sales (ttm): 10.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.21%2016-09 -22.7%2026-06 0.2%-100.9% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 153.1M ÷ 158.7M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.53%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.53%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($5.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.53%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($178.2M) ÷ today's market cap ($8.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.16%2016-09 -26.3%2026-06 2.1%-108.1% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $178.2M + TTM dividends $0) ÷ today's market cap ($8.3B). Same caveat as the cash buyback yield.: 2.16%2016-09 -26.3%2026-06 2.1%-108.1% over the window

Vs own 10Y history

P/S: 16th
P/B: 51st

Bar = where today’s multiple sits in TGTX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-3.62%

-2.53%

-3.37%

-1.75%

YTD

+81.05%

+54.77%

+62.02%

Financial statements

Open full TGTX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

TGTX — TG Therapeutics Inc. price, chart and key statistics